6-K
Bioharvest Sciences Inc. (BHST)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission file number: 001-42389
BIOHARVEST SCIENCES INC.
(Exact name of Registrant as specified in its charter)
Not applicable
(Translation of Registrant’s name into English)
1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☐ Form 20-F ☒ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SUBMITTED HEREWITH Exhibits:
| Exhibit | Description |
|---|---|
| 99.1 | Material Change Report dated July 15, 2026 |
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOHARVEST SCIENCES INC. | |
|---|---|
| (Registrant) | |
| Date: July 15, 2026 | /s/ David Ryan |
| Name: David Ryan | |
| Title: Vice-President, Investor Relations & Secretary |
Material Change Report dated July 15, 2026
FORM 51-102F3
MATERIAL CHANGE REPORT
**Item 1.**Name and Address of Company
BIOHARVEST SCIENCES INC.
Suite 1140 – 625 Howe Street
Vancouver, BC, V6C 2T6
(the “Company” or “BioHarvest”)
**Item 2.**Date of Material Change
July 15, 2026.
**Item 3.**News Release
The news release (the “News Release”) was issued on July 15, 2026 and disseminated by Newsfile Corp.
**Item 4.**Summary of Material Change
The Company announced a US $1.4M grant from the Israel Innovation Authority.
**Item 5.**Full Description of Material Change
The Company announced the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest’s biological development workflows, thereby accelerating its plant cell culture programs.
BioHarvest’s new approved research initiative focuses on moving plant cell culture from traditional empirical trial-and-error methods to a highly predictable, data-driven optimization framework. Specifically, by combining bioinformatics, chemo-informatics and artificial intelligence, the platform will systematically predict the success of plant cell propagation and dramatically maximize active metabolite yields.
Specifically, the program will accelerate the development of BioHarvest's advanced computational discovery engine. This platform integrates proprietary predictive machine learning models with real-time digital sensing to rapidly identify optimal pathways and maximize bioactive yields across diverse plant species. Supported by secure, domain-specific scientific knowledge bases, these new capabilities will streamline early-stage R&D, transforming how complex plant-based compounds are forecasted, monitored, and scaled.
This marks the second grant BioHarvest has received from the Israel Innovation Authority this year. While the first grant was dedicated to scaling the manufacturing facility by integrating industrial automation and machine learning on the factory floor, this second grant is strictly focused on transforming the early-stage R&D pipeline through predictive AI. Together, these two distinct yet highly complementary initiatives fuel a technological transformation across the company - bridging the gap between intelligent, data-driven laboratory discovery and high-volume, autonomous commercial production.[IG1.1]
The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant.
About the Israeli Innovation Authority (IIA)
The Israeli Innovation Authority is a government entity dedicated to fostering Israel’s innovation ecosystem by supporting companies across all stages of technology development, from early research through industrial deployment. For more information, visit https://innovationisrael.org.il/en/.
**Item 6.**Reliance on Subsection 7.1(2) of National Instrument 51-102
Not applicable.
**Item 7.**Omitted Information
None.
**Item 8.**Executive Officer
For further information, please contact:
David Ryan
Secretary and VP, Investor Relations
604 622-1187
**Item 9.**Date of Report
July 15, 2026.